Skip to main content
. Author manuscript; available in PMC: 2013 Apr 1.
Published in final edited form as: Steroids. 2012 Jan 20;77(5):477–483. doi: 10.1016/j.steroids.2012.01.007

Figure 4.

Figure 4

Model structure used to estimate pharmacokinetic parameters of 1,25(OH)2D3 in plasma and tumors. Note how the co-administration of CTA091 is hypothesized to both impact elimination of 1,25(OH)2D3 from the central compartment (Fp), and to inhibit elimination of 1,25(OH)2D3 from the tumor (ktumor-elim).